REVIEW



Meta-analysis: loop ileostomy versus colostomy to prevent complications of anterior resection for rectal cancer

Shilai Yang¹ · Gang Tang² · Yudi Zhang³ · Zhengqiang Wei¹ · Donglin Du¹

Accepted: 25 April 2024 / Published online: 8 May 2024 © The Author(s) 2024

Abstract

Purpose Anastomotic leakage is a serious complication of colorectal cancer surgery, prolonging hospital stays and impacting patient prognosis. Preventive colostomy is required in patients at risk of anastomotic fistulas. However, it remains unclear whether the commonly used loop colostomy(LC) or loop ileostomy(LI) can reduce the complications of colorectal surgery. This study aims to compare perioperative morbidities associated with LC and LI following anterior rectal cancer resection, including LC and LI reversal.

Methods In this meta-analysis, the Embase, Web of Science, Scopus, PubMed, and Cochrane Library databases were searched for prospective cohort studies, retrospective cohort studies, and randomized controlled trials (RCTs) on perioperative morbidity during stoma development and reversal up to July 2023, The meta-analysis included 10 trials with 2036 individuals (2 RCTs and 8 cohorts).

Results No significant differences in morbidity, mortality, or stoma-related issues were found between the LI and LC groups after anterior resection surgery. However, patients in the LC group exhibited higher rates of stoma prolapse (RR: 0.39; 95%CI: 0.19-0.82; P=0.01), retraction (RR: 0.45; 95%CI: 0.29-0.71; P<0.01), surgical site infection (RR: 0.52; 95%CI: 0.27-1.00; P=0.05) and incisional hernias (RR: 0.53; 95%CI: 0.32-0.89; P=0.02) after stoma closure compared to those in the LI group. Conversely, the LI group showed higher rates of dehydration or electrolyte imbalances(RR: 2.98; 95%CI: 1.51-5.89; P<0.01), high-output(RR: 6.17; 95%CI: 1.24-30.64; P=0.03), and renal insufficiency post-surgery(RR: 2.51; 95%CI: 1.01-6.27; P=0.05).

Conclusion Our study strongly recommends a preventive LI for anterior resection due to rectal cancer. However, ileostomy is more likely to result in dehydration, renal insufficiency, and intestinal obstruction. More multicenter RCTs are needed to corroborate this.

Keywords Loop colostomy \cdot Loop ileostomy \cdot Anastomotic leakage \cdot Colorectal cancer

Donglin Du 1093740629@qq.com

- ¹ Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- ² Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- ³ College of Combination of Chinese and Western Medicine, Chongqing College of Traditional Chinese Medicine, No. 61, Puguobao Road, Bicheng Street, Bishan District, Chongqing 402760, P.R. China

Introduction

Colorectal cancer accounts for approximately 10% of newly diagnosed cancers and cancer-related mortalities annually worldwide. Additionally, it is the third most common cancer in men; and the second most common cancer in women worldwide [1, 2]. Three-quarters of all colorectal cancer cases reported are located in the rectal region [3]. Heald's surgical concept of total mesorectal excision (TME) is the mainly adopted routine surgical dissection technique that reduces the local recurrence rate and improves the surgical rates of sphincter-preserving function in rectal cancer. However, anastomotic leakage (AL) remains one of the most frequent complications encountered in anterior resection procedures for all rectal cancer cases [4–6].

Previous reports have confirmed that up to 20% of patients experience AL after undergoing a low or ultralow anterior resection (LAR or uLAR) for rectal cancer [7, 8]. AL is directly linked to local recurrence and a reduction in the overall survival (OS) rate of patients with rectal cancer [9-11]. Therefore, AL is a major concern for surgeons who are now prioritizing finding the best solution for reducing this complication in rectal cancer management. A diverting stoma has been shown to significantly lower the risk of anastomotic leakage, thereby reducing the outcomes of AL [12]. Patients with rectal cancer who are at a higher risk of AL are those with advanced age, obesity, cardiovascular comorbidities, concurrent corticosteroid use, bowel obstruction, neoadjuvant chemoradiotherapy, and a shorter tumor distance from the anal verge. These high risk patients who undergo an anterior resection must have a temporary diverting stoma to prevent AL [13, 14]. However, the choice of stoma technique remains debatable.

The most popular stoma options are the transverse LC or LI. Currently, most surgeons perform a temporary ileostomy. The overall complications of ileostomy are fewer than those of colostomy, and the procedure is simple. With the increasing awareness of the complications of ostomy and the improvement of surgical techniques, some articles tend to favor colostomy. A recent study showed that the overall complication rate was significantly higher in the ileostomy group than in the colostomy group. This is particularly the case with regard to ostomy prolapse, contrary to many previous studies [15]. There is also literature that shows no difference in overall complications between the two [16]. LC and LI, for different populations, the selection of a suitable stoma is key, and the unique complications of LC and LI require further clarification. This study will compile and evaluate the completed trials of LI and LC. Subsequently, updated criteria and continuous meta-analysis will be used to determine the optimal approach.

Methods

This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17]. The study protocol was registered in PROSPERO (CRD42024522102).

Data collection

From inception to July 2023, searches were performed in the databases of Embase, Web of Science, Scopus, Pub-Med, and the Cochrane Library using the keywords: "ileostomy," "colostomy," "rectal cancer," "rectal carcinoma," and "rectal cancer". Figure 1 presents a summary of the search approach.

Criteria for inclusion and exclusion

Inclusion criteria:

- Loop ileostomy or loop colostomy performed during anterior resection in studies involving individuals with colorectal cancer
- Studies designed as cohort studies or randomized controlled trials.

Exclusion criteria:

- Studies involving diverticulitis and other diseases;
- Loop ileostomy or loop colostomy not performed simultaneously during anterior resection;
- Abstracts from meetings, correspondence, reviews, investigations with non-human participants, and case studies
- Trails with duplicate data, such as the same institutional data or overlapping data were excluded.

Study selection

Two review writers independently assessed the abstracts and titles of potential studies to select studies that met our inclusion criteria. The full texts of the papers, which may be of interest, were obtained. The authors identified studies that met the inclusion criteria through independent evaluation of full-text records. Any disagreements regarding study selection were resolved by consensus and discussion among our author group.

Data extraction


Three assessors independently extracted information from the eligible studies, including the author names, publication year, country, sample size, and study duration. Outcome measures included morbidity, mortality, AL and complications associated with stoma creation, such as stoma-prolapse or retraction, stoma-stricture, stoma-bleeding, stoma edema, parastomal dermatitis, parastomal hernia, parastomal infection or sepsis, high output, and renal insufficiency during stoma creation. During stoma closure, the following complications may occur: morbidity, mortality, anastomotic fistula, surgical site infection, incisional hernia, ileus, and the time from operation to first defection and discharge.

Quality assessment

The risk of bias in the RCTs was evaluated using the Cochrane Collaboration tool for risk of bias, which covers the following domains: (a) sequence generation; (b) allocation concealment; (c) participant and staff blinding; (d) blinding of outcome assessment; (e) incomplete outcome data; (f) selective outcome reporting; and (g) additional possible sources of bias. The Newcastle-Ottawa scale (NOS) was used to evaluate the potential for bias in the cohort research. Nine points were allocated for each of the three methodological components evaluated: result, group comparability, and participant selection. Any discrepancies between the three writers (Tang, Du, and Yang) were discussed and solved with the fourth author (Wei) throughout the literature retrieval, screening, information extraction, and quality evaluation processes.

Statistical analysis

The risk ratio (RR) and 95% confidence intervals (CIs) were calculated. For continuous outcome data, the mean difference (MD) and associated 95% CI were computed. Cochran's Q test statistic was used to assess the heterogeneity of the studies. Given the possibility of methodological and clinical heterogeneity, the random-effects model was used in all



quantitative analyses. Review Manager (RevMan) Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration 2014; Copenhagen, Denmark) was used for the analyses. Funnel plot analysis was conducted to assess the publication bias. Statistical significance was set as P < 0.05.

Results

In this study, 3367 articles were initially identified. After removing 1467 duplicate entries, 1900 articles were eliminated based on evaluation of the title and abstract of each article. Subsequently, the remaining 32 papers underwent full-text examination, resulting in the identification of 10 articles that the inclusion criteria for analysis [15, 16, 18–25] (Fig. 1). This meta-analysis comprised 10 trials involving 2036 participants from six countries (China, France, Norway, Turkey, England, and Germany). Table 1 provides an overview of the features of the included studies. Among the ten qualifying studies, there were two RCTs, one prospective cohort study, and seven retrospective cohort studies.

Quality assessment

Eight trials scored five or higher on the NOS, indicating good quality (Table 1). Figure 2 illustrates the low risk of bias observed in the RCTs.

Outcomes

Complications of stoma

Morbidity and mortality following stoma development

Eight studies [15, 16, 18–21, 23, 24] evaluated mortality between the preventive LI and LC groups, while two researchers assessed morbidity [20, 24]. There was no significant difference observed in morbidity (RR: 0.95; 95%CI: 0.61-1.46; P=0.81, Fig. 3A) or mortality (RR: 2.10; 95%CI: 0.45-9.80; P=0.35, Fig. 3B). Furthermore, no heterogeneity was detected among the studies (Tables 2 and 3).

Stoma-related complications

Nine studies [15, 16, 18–21, 23–25] identified stoma-related problems and demonstrated no statistically significant difference between the two groups (RR: 1.07; 95%CI: 0.82–1.41; P=0.62). Significant heterogeneity was observed (P<0.01; $I^2=67\%$) (Fig. 3C).

Stoma prolapse

Seven studies [15, 16, 18–21, 23], concluded that LI reduces the incidence of stoma prolapse (RR: 0.39; 95%CI: 0.19–0.82; P=0.01). The incidence of stoma prolapse was significantly lower in the LI group (1.5%, 9/612) than in the

Table 1 The basic characteristics of included studies

Study/Years	Country	Design	Sample(n)	Age (years	, mean ± sd)	Gender	r (M:F)	BMI or	Obesity	Distance	from anal	interval	NOS
								(n/sar	nple)	verge to	tumour		
										(cm,me	an ± sd)		
			LI/LC	LI	LC	LI	LC	LI	LC	LI	LC	LI/LC	
Edwards/2001	UK	RCT	34/36	NA	NA	27:7	<u>'22:14</u>	NR	NR	NA	NA	62/73d	
Rullier/2001	France	R	107/60	NA	NA	81:26	40:20	O:13	O:19	NR	NR	104/109d	6
Law/2002	China/HK	RCT	42/38	NA	NA	26:16	23:15	NR	NR	6.8	6.4	183/180d	
Gastinger/2005	Germany	Р	NR	NR	NR	N	R	NR	NR	NR	NR	NA	6
Mala /2008	Norway	R	62/10	NR	NR	N	R	NR	NR	NR	NR	NR	5
Sun/ 2019	China	R	66/111	60.2±10.65	61.5±11.24	41:12	68:43	24.3±3.76	24.4±3.15	7.91±3.55	7.73±3.40	NR	7
Wu/2019	China	R	77/109	57.9 ± 10.2	60.7 ± 12.7	52:25	71:38	23.7 ± 2.7	24.2 ± 2.2	NR	NR	201.6/206.2d	8
Prassas/2020	Germany	R	55/93	64.4±13.9	63.1±12.8	38:17	63:30	25.7±5.6	25.3±5.3	NR	NR	NA	8
Çaparlar/2022	Turkey	R	50/40	55.3±5.5	57.5±7.4	29:21	23:17	23.3±3.5	22.5±4.2	11±3	9±4	78/71d	7
Yang/2023	China	R	234/176	64.0±20.0	63.0±20.2	153:81	116:60	23.1±4.8	22.4±4.4	NR	NR	NA	7

O Obesity, Rct Randomized controlled trial, P Prospective cohort study, R Retrospective cohort study, NR Not reported, NA No significance




Fig. 2 Risk of bias for each included RCT study. A Risk of bias summary. B Risk of bias graph

LC group (4.0%, 25/623). There was no discernible heterogeneity between the two groups. (P=0.92, $I^2=0\%$) (Fig. 4A).

Stoma retraction

Seven studies [15, 16, 18–21, 25] reported data of stoma retraction and a comprehensive analysis revealed that stoma stricture was significantly lower in the LI group (4.0%,25/628)compared to the LC group (7.3%,46/627), with no observed heterogeneity (RR: 0.45; 95%CI: 0.29–0.71; P < 0.01; heterogeneity: P = 0.64, $I^2 = 0\%$)(Fig. 4B).

Stoma stricture

A comprehensive analysis of two studies [15, 19] reporting on stoma stricture showed no significant difference in stoma stricture between the LI and LC groups (RR: 0.79; 95%CI: 0.03-19.53; P=0.89; heterogeneity: P=0.1, I²=64%) (Fig. 4C).

Stoma bleeding and edema

No discernible difference in stoma hemorrhage and edema between the LI and LC groups was observed in five investigations [15, 16, 18, 19, 25]. (RR: 1.20; 95%CI: 0.50–2.88; P=0.68; heterogeneity: P=0.67, $I^2=0\%$) (Fig. 4D).

Parastomal dermatitis

Combined analysis from seven studies [15, 16, 18–21, 25] indicated that parastomal dermatitis did not significantly differ between the LI and LC groups, although the LI group showed a trend toward have more parastomal dermatitis than the LC group (RR: 1.63; 95%CI: 0.95–2.82; P=0.08; heterogeneity: P=0.008, I²=65%) (Fig. 5A).

Parastomal hernia

In the nine studies [15, 16, 18–21, 23–25] regarding parastomal hernia, no discernible difference was observed between the LI and LC groups (RR: 0.77; 95%CI: 0.47–1.26; P=0.29; heterogeneity: P=0.29, $I^2 = 17\%$) (Fig. 5B).

Necrosis

Comprehensive analysis revealed no significant difference in stoma necrosis between the LI and LC groups (RR: 0.52; 95%CI: 0.06–4.18; P=0.54; heterogeneity: P=0.93, $I^2 = 0\%$) (Fig. 5C). Two studies reported stoma necrosis [19, 21].

А		LI		LC			Risk Ratio	Risk Ratio
-	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
	2002 Law	19	42	19	38	88.9%	0.90 [0.57, 1.43]	
	2008 Mala	17	62	2	10	11.1%	1.37 [0.37, 5.05]	
	Total (95% CI)		104		48	100.0%	0.95 [0.61, 1.46]	+
	Total events	36		21				
	Heterogeneity: Tau ² = 0	0.00; Chi ²	= 0.36	, df = 1 (F	P = 0.55); l ² = 0%		0.01 0.1 1 10 100
	Test for overall effect: 2	Z = 0.24 (P = 0.8	1)				Favours [LI] Favours [LC]
В		LI		LC			Risk Ratio	Risk Ratio
_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
	2001 Edwards	0	34	0	36		Not estimable	
	2001 Rullier	0	107	0	60		Not estimable	
	2002 Law	2	42	0	38	26.3%	4.53 [0.22, 91.57]	
	2008 Mala	2	62	0	10	27.0%	0.87 [0.04, 16.98]	
	2019 Sun	0	66	0	111		Not estimable	
	2019 Wu	0	77	0	109		Not estimable	
	2020 Prassas	0	55	0	93		Not estimable	
	2023 Yang	3	234	1	176	46.7%	2.26 [0.24, 21.51]	
	Total (95% CI)		677		633	100.0%	2.10 [0.45, 9.80]	
	Total events	7		1				
	Heterogeneity: Tau ² = 0	0.00; Chi ²	= 0.60	df = 2 (F	e = 0.74); $ ^2 = 0\%$		
	Test for overall effect: 2							0.01 0.1 1 10 100 Favours [LI] Favours [LCI]
				,				Favours [LI] Favours [LCI]
C		LI		LC			Risk Ratio	Risk Ratio
-	Study or Subgroup					-	M-H, Random, 95% Cl	M-H, Random, 95% Cl
	2001 Edwards	1	34	10	36	1.7%	0.11 [0.01, 0.78]	·
	2001 Rullier	20	107	21	60	11.9%	0.53 [0.32, 0.90]	
	2002 Law	6	39	11	38	6.5%	0.53 [0.22, 1.29]	
	2008 Mala	16	62	2	10	3.6%	1.29 [0.35, 4.78]	-
	2019 Sun	49	66	54	111	18.4%	1.53 [1.20, 1.94]	-
	2019 Wu	48	77	57	109	18.2%	1.19 [0.93, 1.53]	
	2020 Prassas	17	55	25	93	12.1%	1.15 [0.68, 1.93]	
	2022 Çaparlar	20	50	9	40	9.3%	1.78 [0.91, 3.47]	_
	2023 Yang	102	234	64	176	18.3%	1.20 [0.94, 1.53]	-

Heterogeneity: Tau² = 0.09; Chi² = 24.48, df = 8 (P = 0.002); $I^2 = 67\%$ Test for overall effect: Z = 0.50 (P = 0.62)

Fig. 3 The morbidity (A), mortality (B) and stoma-related complication (C) in the stoma formation between LI and LC groups

673 100.0%

Parastomal infection and sepsis

Total (95% CI)

Total events

Analysis from three studies [15, 18, 19] indicated that parastomal infection & sepsis did not significantly differ between LI and LC groups (RR: 0.60; 95%CI: 0.17–2.16; P = 0.43; heterogeneity: P = 0.18, $I^2 = 41\%$) (Fig. 5D).

724

253

279

Dehydration or electrolyte disturbance

In each of the five trials [15, 19, 21, 24, 25], the LI group had a higher incidence of dehydration or electrolyte disruption

than the LC group, with no heterogeneity observed. (Fig. 6A): (RR: 2.98; 95%CI: 1.51–5.89; P < 0.01; heterogeneity: P = 0.83, $I^2 = 0\%$).

0.1

1

Favours [LI] Favours [LC]

100

10

High-output

1.07 [0.82, 1.41]

0.01

A combination of four studies [18, 20, 23, 25] suggests that the LI group (8.1%,29/357) had a higher incidence of high-out stomas compared to the LC group (0%, 0/290). (RR: 6.17; 95%CI: 1.24–30.64; P=0.03; heterogeneity: P=0.35, $I^2=9\%$) (Fig. 6B).

Table 2 Outcomes related to stoma formation

 I^2

0% 0% 67% 0% 64% 0% 65% 17% 0% 41% 0%

9%

0%

	LI(events/total, n)	LC(events/total, n)	Statistical method, RR	Estimated effect, 95%CI
Morbidity following stoma development	36/104	21/48	0.95	0.61-1.46
Mortality following stoma development	7/677	1/633	2.10	0.45-9.80
Stoma-related complication	279/724	253/673	1.07	0.82-1.41
Stoma prolapse	9/612	25/623	0.39	0.19-0.82
Stoma retraction	25/628	46/627	0.45	0.29-0.71
Stoma stricture	2/173	3/171	0.79	0.03-19.53
Stome bleeding and edema	10/512	10/480	1.20	0.50-2.88
Parastomal dermatitis	120/628	73/627	1.63	0.95-2.82
Parastomal hernia	39/724	64/673	0.77	0.47-1.26
Necrosis	1/184	2/169	0.52	0.06-4.18
Parastomal infection & sepsis	7/407	11/347	0.60	0.17-2.16
Dehydration or Electrolyte disturbance	27/362	9/330	2.98	1.51-5.89

0/290

6/378

LI Loop ileostomy, LC Loop colostomy, CI Confidence interval, RR Risk ratio

29/357

15/366

Renal insufficiency

High-output Renal insufficiency

A combination of three studies [16, 18, 21] indicated that patients from the LI group (4.1%, 15/366) were more likely to experience renal insufficiency compared to patients from the LC group (1.6%, 6/378) (RR: 2.51; 95%CI: 1.01–6.27; P=0.05; heterogeneity: P=0.43, $I^2=0\%$) (Fig. 6C).

Complications following stoma closure

Morbidity after stoma reversal

Between the two types of stomas, four studies [18, 20, 22, 24] compared morbidity following stoma reversal and found no statistically significant difference. (RR: 1.15; 95%CI: 0.77–1.72; P=0.49; heterogeneity: P=0.18, $I^2=39\%$) (Fig. 7A).

Mortality after stoma reversal

Four studies [18, 20, 22, 24] evaluated mortality rates between the LI and LC groups following stoma reversal. There was no discernible difference (RR: 1.23; 95%CI: 0.23-6.64; P = 0.81; heterogeneity: P = 0.80, I² = 0%) (Fig. 7B) between the two group.

1.24-30.64

1.01-6.27

6.17

2.51

Stoma closure-related complication

Eight studies [15, 16, 18–22, 25] revealed specific postoperative problems. The findings indicated that there was no statistically significant difference between the two groups (RR: 1.03; 95%CI: 0.68–1.55; P=0.90; heterogeneity: P < 0.01, $I^2 = 65\%$) (Fig. 7C).

Table 3	Outcomes	related	to stoma	l closure
---------	----------	---------	----------	-----------

	LI(events/total, n)	LC(events/total, n)	Statistical method, RR	Estimated effect, 95%CI	I2
Morbidity after stoma reversal	151/691	76/421	1.15	0.77-1.72	39%
Mortality after stoma reversal	5/691	1/421	1.23	0.23-6.64	0%
Stoma closure-related complication	173/964	138/785	1.03	0.68-1.55	65%
Anastomotic fistula	15/803	6/642	1.35	0.46-4.01	11%
Surgical site infections (SSI)	32/642	60/597	0.52	0.27-1.00	41%
Incisional hernia	22/554	44/549	0.53	0.32-0.89	0%
Ileus	48/794	20/596	1.59	0.94-2.69	1%

LI Loop ileostomy, LC Loop colostomy, CI Confidence interval, RR Risk ratio

۸		LI		LC			Risk Ratio	Risk Ratio	
A	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	CI M-H. Random, 95% CI	
	2001 Edwards	0	34	2	36	6.0%	0.21 [0.01, 4.25]	5]	
	2001 Rullier	4	107	6	60	35.7%	0.37 [0.11, 1.27]	·] — — — — — — — — — — — — — — — — — — —	
	2002 Law	0	39	3	38	6.2%	0.14 [0.01, 2.61]		
	2019 Sun	2	66	5	111	20.7%	0.67 [0.13, 3.37]	·]	
	2019 Wu	1	77	3	109	10.6%	0.47 [0.05, 4.45]	5]	
	2020 Prassas	1	55	2	93	9.5%	0.85 [0.08, 9.11]	J	
	2023 Yang	1	234	4	176	11.3%	0.19 [0.02, 1.67]	n <u> </u>	
	Total (95% CI)		612		623	100.0%	0.39 [0.19, 0.82]	ı 🔶	
	Total events	9		25					
	Heterogeneity: Tau ² = (0.00; Chi ²	= 1.96	, df = 6 (F	P = 0.92	2); l² = 0%			H L
	Test for overall effect: 2	Z = 2.50 (P = 0.0	1)				Favours [LI] Favours [LC]	U

В		LI		LC			Risk Ratio		Risk	Ratio	
Ъ.	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rand	om, 95% Cl	
	2001 Rullier	0	107	3	60	2.4%	0.08 [0.00, 1.54]	←	-	—	
	2002 Law	0	39	0	38		Not estimable				
	2019 Sun	0	66	2	111	2.3%	0.33 [0.02, 6.86]		· · ·		
	2019 Wu	0	77	1	109	2.0%	0.47 [0.02, 11.39]		•		
	2020 Prassas	1	55	1	93	2.7%	1.69 [0.11, 26.49]			· ·	
	2022 Çaparlar	2	50	1	40	3.7%	1.60 [0.15, 17.02]				
	2023 Yang	22	234	38	176	86.9%	0.44 [0.27, 0.71]		-		
	Total (95% CI)		628		627	100.0%	0.45 [0.29, 0.71]		•		
	Total events	25		46							
	Heterogeneity: Tau ² = (0.00; Chi ²	= 3.36	, df = 5 (F	e = 0.64); l² = 0%					100
	Test for overall effect: 2	Z = 3.41 (P = 0.0	006)				0.01	0.1 Favours [LI]	l 10 Favours [LC]	100

C		LI		LC			Risk Ratio		Risk	Ratio	
U	Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	5	M-H. Rand	lom, 95% Cl	
	2001 Rullier	1	107	3	60	56.1%	0.19 [0.02, 1.76]	5		-	
	2019 Sun	1	66	0	1 11	43.9%	5.01 [0.21, 121.35]				
	Total (95% Cl)		173		171	100.0%	0.79 [0.03, 19.53]				
	Total events	2		3							
	Heterogeneity: Tau ² =	3.46; Chi ²	= 2.75	df = 1 (F	= 0.10); ² = 64%	6				400
	Test for overall effect:	Z = 0.14 (P = 0.8	9)				0.01	0. 1 Favours [LI]	1 10 Favours [LC]	100

D		LI		LC			Risk Ratio		Risk Ratio	
D_{-}	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Random, 95% C	1
	2001 Rullier	0	107	1	60	7.6%	0.19 [0.01, 4.55]	←		
	2019 Sun	5	66	6	111	58.4%	1.40 [0.45, 4.41]			
	2020 Prassas	0	55	1	93	7.6%	0.56 [0.02, 13.50]		•	_
	2022 Çaparlar	1	50	1	40	10.2%	0.80 [0.05, 12.40]			_
	2023 Yang	4	234	1	176	16.1%	3.01 [0.34, 26.68]			
	Total (95% CI)		512		480	100.0%	1.20 [0.50, 2.88]		-	
	Total events	10		10						
	Heterogeneity: Tau ² =	0.00; Chi ²	= 2.36	, df = 4 (F	P = 0.67	'); ² = 0%				+ 100
	Test for overall effect:	Z = 0.41 (P = 0.6	8)				0.01	0.1 1 1 Favours [LI] Favours [L	10 100 .C]

Fig. 4 The stoma prolapse (A), stoma retraction (B), stoma stricture (C), and stoma bleeding and edema (D) between LI and LC groups

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	٨											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	A	LI		LC			Risk Ratio	Risk Ratio				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	24 COM CONTRACTOR (100 CONTRACTOR)						a service of the service of the service of the	M-H, Random, 95% Cl				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $							• • •					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							• • •					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		5			93							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	•				40		1.44 [0.52, 3.96]					
Total events 120 73 Heterogeneity: Tau ² = 0.29; Ch ² = 17.28, df = 6 (P = 0.008); P = 65% 0.01 0.1 1 10 100 B Ll LC Risk Ratio Risk Ratio Risk Ratio 2001 Edwards 0 34 1 38 2.3% 0.35 (0.01, 8.38) 0.4 Heterogeneity: Tau ² = 0.00; Ch ² =	2023 Yang	49	234	26	176	22.9%	1.42 [0.92, 2.19]	T-				
Total events 120 73 Heterogeneity: Tau ² = 0.29; Ch ² = 17.28, df = 6 (P = 0.008); P = 65% 0.01 0.1 1 10 100 B Ll LC Risk Ratio Risk Ratio Risk Ratio 2001 Edwards 0 34 1 38 2.3% 0.35 (0.01, 8.38) 0.4 Heterogeneity: Tau ² = 0.00; Ch ² =	Total (95% CI)		628		627	100.0%	1.63 [0.95, 2.82]	•				
Heterogeneity: Tau ² = 0.28; Ch ² = 17.28, df = 6 (P = 0.008); P = 65% 0.01 0.1 0.1 1 10 B Li LC Risk Ratio Risk Ratio Risk Ratio 2001 Edwards 0 34 1 36 2.3% 0.35 (0.01, 8.36) 2001 Edwards 0 34 1 36 2.3% 0.35 (0.01, 8.36) 2001 Edwards 0 34 1 36 2.3% 0.22 (0.04, 1.12) 2002 Law 1 39 0 38 2.3% 2.29 (0.12, 6.96 4) 2003 Passas 11 1.5 2.1 93 31.0% 0.89 [0.46, 1.69] 2020 Prassas 11 55 2.1 93 31.0% 0.89 [0.46, 1.69] 2022 Caparlar 2 5.0 1.40 4.0% 1.60 [0.15, 17.02] 2023 Yang 3 2.24 0 176 2.6% 5.27 [0.27, 101.42] Total (95% Cl) 724 673 100.0% 0.77 [0.47, 1.26] 0.01 0.1 1.01 100 Study or Subgroup Events Total (95% Cl) 1.8		120		73								
Test for overall effect: Z = 1.76 (P = 0.08) UIT UIT UIT UIT UIT Favours [L] B LI LC Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random, 95% CI 2001 Edwards 0 34 1 36 8.15 C 2001 Edwards 0 33 10.9 2.9 10.2 Risk Ratio M-H. Random, 95% CI 2001 Rullier 1 39 0 33 10.0 2.9 10.1 C Risk Ratio Risk for overall effect: Z = 1.05 (P = 0.29) 17 100 0.05 C LI LC Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random, 95% CI M-H. Random, 95% CI Stud			= 17 2		P = 0.0	08): I ² = 6	5%	⊢−−−− −−− − −−− −				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $,						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				-,				Favours [LI] Favours [LC]				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	R	LI		LC			Risk Ratio	Risk Ratio				
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$			Total		Total	Weiaht						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							• •					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				-				_				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							• • •	_ _				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								 _				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
Total (95% Cl) 724 673 100.0% 0.77 [0.47, 1.26] Total events 39 64 Heterogeneity: Tau ² = 0.09; Ch ² = 9.67, df = 8 (P = 0.29); l ² = 17% 0.01 0.1 1 10 100 Test for overall effect: Z = 1.05 (P = 0.29) LL C Risk Ratio Risk Ratio Risk Ratio C LL LC Risk Ratio M-H. Random. 95% Cl M-H. Random. 95% Cl 2001 Rullier 1 107 1 60 57.3% 0.56 [0.04, 8.80] 2019 Wu 0 77 1 109 42.7% 0.47 [0.02, 11.39] Total (95% Cl) 184 169 100.0% 0.52 [0.06, 4.18] Total events 1 2 Risk Ratio Risk Ratio D Ll LC Risk Ratio Risk Ratio Study or Subgroup Events Total (P = 0.93); l ² = 0% 0.47 [0.02, 11.39] Risk Ratio O Ll LC Risk Ratio M-H. Random. 95% Cl M-H. Random. 95% Cl O Ll LC Risk Ratio M-H. Random. 95% Cl M-H. Random. 95% Cl <							• • •					
Total events 39 64 Heterogeneity: Tau ² = 0.09; Chi ² = 9.67, df = 8 (P = 0.29); I ² = 17% 0.01 0.1 1 100 C Ll LC Risk Ratio Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random. 95% CI 2001 Rullier 1 107 1 60 57.3% 0.56 [0.04, 8.80] 2019 Wu 0 77 1 109 42.7% 0.47 [0.02, 11.39] Total (95% CI) 184 169 100.0% 0.52 [0.06, 4.18] Total events 1 2 Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); I ² = 0% 0.47 [0.02, 11.39] Total events 1 2 Heterogeneity: Tau ² = 0.62 (P = 0.54) Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random. 95% CI 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 11 36.6% 1.68 [0.35, 8.09] 0.56 [0.13, 2.49] <td>2025 rang</td> <td>5</td> <td>234</td> <td>0</td> <td>170</td> <td>2.0%</td> <td>5.27 [0.27, 101.42]</td> <td></td>	2025 rang	5	234	0	170	2.0%	5.27 [0.27, 101.42]					
Heterogeneily: Tau ² = 0.09; Chi ² = 9.67, df = 8 (P = 0.29); l ² = 17% Test for overall effect: Z = 1.05 (P = 0.29) C LI LC Risk Ratio Risk Ratio M-H. Random, 95% CI Risk Ratio O H-H. Random, 95% CI O O 1 0.1 1 10 100 Favours [LC] Favours [LC] I 0.01 0.1 1 10 100 Favours [LC] I 0 0.01 0.1 1 1 0 100 Favours [LC] I 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total (95% CI)		724		673	100.0%	0.77 [0.47, 1.26]	◆				
Test for overall effect: $Z = 1.05$ (P = 0.29) Interpretation of the second se	Total events	39		64								
Test for overall effect: $Z = 1.05$ (P = 0.29) Favours [LI] Favours [LC] Favours [LI] Favours [LC] C LI LC Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random. 95% CI 2001 Rullier 1 107 1 60 57.3% 0.56 [0.04, 8.80] 2019 Wu 0 77 1 109 42.7% 0.47 [0.02, 11.39] Total (95% CI) 184 169 100.0% 0.52 [0.06, 4.18] Total events 1 2 Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); l ² = 0% 0.01 0.1 1 10 100 Favours [LI] Favours [LC] Events Total (95% CI) 10 10 100 Favours [LI] Favours [LC] Favours [LI] Favours [LC] Favours [LI] Favours [LC] D LI LC Risk Ratio Study or Subgroup Events Total Yeight M-H. Random. 95% CI M-H, Random. 95% CI M-H, Random. 95% CI M-H,	Heterogeneity: Tau ² =	0.09; Chi ²	= 9.67	, df = 8 (F	P = 0.29	9); l² = 17%	6					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Test for overall effect:	Z = 1.05 (F	P = 0.2	9)								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	С											
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl				
Total (95% Cl) 184 169 100.0% 0.52 [0.06, 4.18] Total events 1 2 Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); l ² = 0% 0.01 0.1 1 100 Test for overall effect: Z = 0.62 (P = 0.54) LI LC Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 2023 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 10 100 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100	2001 Rullier	1	107	1	60	57.3%	0.56 [0.04, 8.80]					
Total events 1 2 Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); l ² = 0% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.62 (P = 0.54) LI LC Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 2023 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100	2019 Wu	0	77	1	109	42.7%	0.47 [0.02, 11.39]					
Total events 1 2 Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); l ² = 0% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.62 (P = 0.54) LI LC Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 2023 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100												
Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); l ² = 0% D LI LC Risk Ratio Meterogeneity: Tau ² = 0.02 (P = 0.54) D LI LC Risk Ratio Meterogeneity: Tau ² = 0.62 (P = 0.54) D LI LC Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 0.44, Random, 95% CI 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 0.23 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] 0.01 0.1 1 0.01 0.1 1 10 100 Total (95% CI) 407 347 100.0% 0.60 [0.17, 2.16] 0.01 0.1 1 10 100 Total (95% CI) 2 = 41% <t< td=""><td>Total (95% CI)</td><td></td><td>184</td><td></td><td>169</td><td>100.0%</td><td>0.52 [0.06, 4.18]</td><td></td></t<>	Total (95% CI)		184		169	100.0%	0.52 [0.06, 4.18]					
Test for overall effect: $Z = 0.62 (P = 0.54)$ OUNT OUNT <th col<="" td=""><td></td><td>•</td><td></td><td>_</td><td></td><td></td><td></td><td> </td></th>	<td></td> <td>•</td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td> </td>		•		_							
Test for overall effect: $Z = 0.62$ (P = 0.54) Favours [LI] Favours [LC] Test for overall effect: $Z = 0.62$ (P = 0.54) Favours [LI] Favours [LC] Total Events Total Weight M-H. Random. 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total (95% Cl) 407 347 10 Total (95% Cl) 407 347 10 Total events <th <="" colspan="4" td=""><td></td><td></td><td></td><td></td><td>P = 0.93</td><td>3); I² = 0%</td><td></td><td></td></th>	<td></td> <td></td> <td></td> <td></td> <td>P = 0.93</td> <td>3); I² = 0%</td> <td></td> <td></td>								P = 0.93	3); I² = 0%		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Test for overall effect:	Z = 0.62 (F	P = 0.5	4)								
Study or Subgroup Events Total Events Total Weight M-H. Random, 95% Cl M-H. Random, 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 100												
Study or Subgroup Events Total Events Total Weight M-H. Random, 95% Cl M-H. Random, 95% Cl 2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 100	D	ш		LC			Risk Ratio	Risk Ratio				
2001 Rullier 1 107 4 60 24.5% 0.14 [0.02, 1.23] 2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 2023 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100			Total		Total	Weight						
2019 Sun 3 66 3 111 36.6% 1.68 [0.35, 8.09] 2023 Yang 3 234 4 176 38.9% 0.56 [0.13, 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100						-						
2023 Yang 3 234 4 176 38.9% 0.56 [0.13 , 2.49] Total (95% Cl) 407 347 100.0% 0.60 [0.17 , 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53 ; Chi ² = 3.40 , df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100												
Total (95% Cl) 407 347 100.0% 0.60 [0.17, 2.16] Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100							• • •	_				
Total events 7 11 Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% 0.01 0.1 1 10 100	2020 rany	3	204	4	170	00.9%	0.00 [0.10, 2.49]	_				
Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% Tot for everall effect: $Z = 0.78$ (P = 0.43) 0.01 0.1 1 10 100	Total (95% CI)		407		347	100.0%	0.60 [0.17, 2.16]					
Heterogeneity: Tau ² = 0.53; Chi ² = 3.40, df = 2 (P = 0.18); l ² = 41% Tot for everall effect: $Z = 0.78$ (P = 0.43) 0.01 0.1 1 10 100		7		11			-					
Test for sylerall effect: Z = 0.78 /B = 0.43)		-	= 3.40		P = 0.18	3); ² = 41%	6					
Favours [LI] Favours [LC]						,						
				,				Favours [LI] Favours [LC]				

А		LI		LC			Risk Ratio	Risk Ratio
Л.	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
	2001 Rullier	4	107	0	60	5.5%	5.08 [0.28, 92.83]	
	2008 Mala	1	62	0	10	4.7%	0.52 [0.02, 12.05]	
	2019 Sun	1	66	0	111	4.6%	5.01 [0.21, 121.35]	,
	2019 Wu	18	77	8	109	75.9%	3.19 [1.46, 6.95]	
	2022 Çaparlar	3	50	1	40	9.3%	2.40 [0.26, 22.20]	
	Total (95% CI)		362		330	100.0%	2.98 [1.51, 5.89]	◆
	Total events	27		9				
	Heterogeneity: Tau ² =	0.00; Chi ²	= 1.48	, df = 4 (F	9 = 0.83	s); l² = 0%		0.01 0.1 1 10 100
	Test for overall effect: 2	Z = 3.15 (P = 0.0	02)				6.01 0.1 1 10 100 Favours [LI] Favours [LC]
В		LI		LC			Risk Ratio	Risk Ratio
υ.	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
	2001 Edwards	1	34	0	36	23.5%	3.17 [0.13, 75.28]	
	2002 Law	1	39	0	38	23.5%	2.92 [0.12, 69.64]	
	2022 Çaparlar	1	50	0	40	23.4%	2.41 [0.10, 57.65]	
	2023 Yang	26	234	0	176	29.6%	39.92 [2.45, 650.59]	_ →
	Total (95% CI)		357		290	100.0%	6.17 [1.24, 30.64]	
	Total events	29		0				
	Heterogeneity: Tau ² =	0.23; Chi ²	= 3.28	, df = 3 (F	9 = 0.35	i); l² = 9%		0.01 0.1 1 10 100
	Test for overall effect: 2	Z = 2.23 (P = 0.0	3)				0.01 0.1 1 10 100 Favours [LI] Favours [LC]
C		LI		LC			Risk Ratio	Risk Ratio
C	Study or Subaroup		Total	Events	Total	Weight	M-H. Random, 95% C	M-H, Random, 95% Cl
	2019 Wu	8	77	6	109	80.8%	1.89 [0.68, 5.22]	
	2020 Prassas	2	55	0	93	9.2%	8.39 [0.41, 171.69]	_
	2023 Yang	5	234	0	176	10.0%	8.29 [0.46, 148.85]	
	Ũ						• • •	
	Total (95% CI)		366		378	100.0%	2.51 [1.01, 6.27]	
	Total events	15		6				
	Heterogeneity: Tau ² =	0.00; Chi ²	= 1.68	, df = 2 (F	9 = 0.43	s); l ² = 0%		
	Test for overall effect: 2	Z = 1.97 (P = 0.0	5)		-		
				-				Favours [LI] Favours [LC]

Fig. 6 The Dehydration or Electrolyte disturbance (A), High-output (B) and renal insufficiency (C) between LI and LC groups

Anastomotic fistula

Evidence from a combination of eight studies [15, 16, 19–24] suggests no significant differences regarding anastomotic fistula after stoma reversal between the LI and LC groups (RR: 1.35; 95%CI: 0.46–4.01; P=0.58; heterogeneity: P=0.34, $1^2 = 11\%$) (Fig. 7D).

Surgical site infections (SSI)

Nine studies [15, 16, 18–21, 23–25] published SSI data. Combining the data, the analysis revealed a statistically significant difference in the incidence of SSI between the LI group (5.0%, 32/642) and the LC group (10.1%, 60/597) following stoma reversal. This suggests that LI is less likely than LC to experience SSI (RR: 0.52; 95%CI: 0.27–1.00; P=0.05; heterogeneity: P=0.11, $I^2=41\%$) (Fig. 8A).

Incisional hernia

Seven studies [15, 16, 18, 19, 21, 23, 25] reported incisional hernias after stoma closure. Combined analysis showed that the patients from the LI group (4.0%, 22/554) had a lower incisional hernia when compared to patients from the LC group (8.0%, 44/549) (RR: 0.53; 95%CI: 0.32–0.89; P=0.02; heterogeneity: P=0.47, $I^2=0\%$) (Fig. 8B).

lleus

Six studies [15, 16, 18, 20, 22, 24] reported data on ileus after stoma reversal. Combined analysis showed that a significantly higher incidence of ileus in the LI group (6.0%, 48/794) compared to the LC group (3.4%, 20/596) (RR: 1.59; 95%CI: 0.94–2.69; P=0.08; heterogeneity: P=0.40, I^2 =1%) (Fig. 8C).

Α	o			LC			Risk Ratio	Risk Ratio
	Study or Subgroup					Weight	M-H. Random, 95% Cl	M-H, Random, 95% Cl
	2002 Law	4	35	5	38	9.2%	0.87 [0.25, 2.98]	
	2005 Gastinger	91	407	35	229	45.2%	1.46 [1.03, 2.09]	
	2008 Mala	15 41	53	1 35	10	4.1%	2.83 [0.42, 19.08]	-
	2023 Yang	41	196	35	144	41.5%	0.86 [0.58, 1.28]	
	Total (95% CI)		691		421	100.0%	1.15 [0.77, 1.72]	•
	Total events	151		76	-12-1	100.070		Ť
	Heterogeneity: Tau ² =		= 4 92		P = 0.18): $l^2 = 39\%$, ⊢	I I
	Test for overall effect:			-	0.10), 1 - 00 /	, 0	0.01 0.1 1 10 10
		_ 0.00 (.		- /				Favours [LI] Favours [LC]
		LI		LC			Risk Ratio	Risk Ratio
В	Study or Subgroup		Total		Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
	2002 Law	0	35	0	38	Weight	Not estimable	M-H, Kandolii, 3378 Ci
	2002 Law 2005 Gastinger	2	407	0	229	30.8%	2.82 [0.14, 58.46]	
	2008 Mala	2	53	0	10	32.2%	1.02 [0.05, 19.78]	_
	2023 Yang	1	196	1	144	37.1%	0.73 [0.05, 11.65]	_
	2020 Tang		150	'	144	07.170	0.70 [0.00, 11.00]	
	Total (95% CI)		691		421	100.0%	1.23 [0.23, 6.64]	
	Total events	5		1				
	Heterogeneity: Tau ² =	0.00; Chi ²	= 0.44		9 = 0.80); I ² = 0%	H	
	Test for overall effect:					,.	0	
				,				Favours [LI] Favours [LC]
~		L	I	LC	;		Risk Ratio	Risk Ratio
С	Study or Subgroup	Events	s Tota	l Events	s Tota	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
	2001 Rullier	12	2 96	37	50	11.0%	0.89 [0.38, 2.13]	
	2002 Law	4	4 35	5 3	38 38	6.0%	1.45 [0.35, 6.02]	
	2005 Gastinger	76	3 4 07	7 30) 229	18.1%	1.43 [0.96, 2.11]	
	0040 0			3 10) 111	12.9%	2.69 [1.30, 5.58]	
	2019 Sun	16	66) IL	, ,,,		Figo [1196] 9196]	l l
	2019 Sun 2019 Wu	16 6					0.29 [0.13, 0.67]	
	2019 Wu 2020 Prassas	6	6 77 8 37	29 7 14	0 109 64) 11.5% 12.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13]	
	2019 Wu 2020 Prassas 2022 Çaparlar	6 8 8	6 77 8 37 8 50	29 7 14 0 6	9 109 64 6 40) 11.5% 12.3%) 9.8%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82]	
	2019 Wu 2020 Prassas	6	6 77 8 37 8 50	29 7 14 0 6	9 109 64 6 40) 11.5% 12.3%) 9.8%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13]	
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang	6 8 8	5 77 3 37 3 50 3 196	29 7 14 9 6 3 39	9 109 64 6 40 9 144	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18]	
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI)	6 8 8 43	6 77 3 37 3 50 3 196 96 4	29 7 14 9 6 3 39	9 109 64 64 64 64 64 64 64 64 64 64 64 64 64	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82]	
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events	6 8 43 173	5 77 3 37 3 50 3 196 964	29 7 14 9 6 3 39 138	9 109 64 63 40 9 144 785	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55]	
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ²	6 8 43 173 = 0.20; Ch	5 77 3 37 3 50 3 196 964 3 1 ² = 20.	29 7 14 9 6 3 39 138 07, df = 7	9 109 64 63 40 9 144 785	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55]	
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events	6 8 43 173 = 0.20; Ch	5 77 3 37 3 50 3 196 964 3 1 ² = 20.	29 7 14 9 6 3 39 138 07, df = 7	9 109 64 63 40 9 144 785	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55]	0.01 0.1 1 10 1 Favours [Ll] Favours [LC]
	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ²	6 8 43 = 0.20; Ch t: Z = 0.13	5 77 3 37 3 50 3 196 964 3 1 ² = 20.	7 29 7 14 9 6 3 39 138 07, df = 7 90)	9 109 64 63 40 9 144 785	11.5% 12.3% 9.8% 18.3%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65%	Favours [LI] Favours [LC]
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect	6 8 43 173 = 0.20; Ch t: Z = 0.13 Ll	6 77 3 37 3 50 3 196 954 3 i ² = 20. (P = 0.	29 7 14 9 6 3 39 138 07, df = 7 90)	9 109 64 63 40 9 144 785 3 7 (P = 0	9 11.5% 12.3% 9 9.8% 18.3% 5 100.0%	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect	6 8 43 = 0.20; Ch t: Z = 0.13 Ll Events	6 77 3 37 3 50 8 196 954 3 i ² = 20. (P = 0.	297 14 1 6 3 39 138 07, df = 7 90) LC Events	9 109 64 6 40 144 785 7 785 7 785	9 11.5% 12.3% 9 9.8% 18.3% 5 100.0% 005); ² =	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio M-H. Random, 95% Cl	Favours [LI] Favours [LC]
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards	6 8 43 173 = 0.20; Ch t: Z = 0.13 Ll <u>Events</u> 0	5 77 3 37 3 50 8 196 954 3 i ² = 20. (P = 0. <u>Total</u> 32	7 29 7 14 0 6 3 39 136 07, df = 7 90) LC <u>Events</u> 1	 109 64 40 144 785 3 (P = 0. Total 31 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% Cl</u> 0.32 [0.01, 7.65]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Rullier	6 8 43 = 0.20; Ch t: Z = 0.13 Ll <u>Events</u> 0 0	6 77 3 37 3 50 954 954 3 196 954 196 196 196 196 196 196 196 196	297 14 0 6 39 138 07, df = 7 90) LC <u>Events</u> 1 2	 9 109 64 64 785 3 (P = 0. 7 (P = 0. 31 50 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = <u>Weight</u> 10.6% 11.6% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random. 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] ←	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Rullier 2002 Law	6 8 43 = 0.20; Ch t: Z = 0.13 Ll <u>Events</u> 0 0 1	5 77 3 37 3 50 954 3 i ² = 20. (P = 0. <u>Total</u> 32 96 35	297 14 0 6 39 138 07, df = 7 90) LC <u>Events</u> 1 2 0	 109 64 40 144 785 7(P = 0. 31 50 38 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 11.6% 10.6% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random. 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger	6 8 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9	5 77 3 37 3 50 954 954 3 i ² = 20. (P = 0. <u>Total</u> 32 96 35 407	297 14 0 6 3 39 138 07, df = 7 90) LC Events 1 2 0 0	 109 64 40 144 785 (P = 0. (P = 0. 31 30 38 229 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 11.6% 10.6% 12.9% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] ← 3.25 [0.14, 77.25] 10.71 [0.63, 183.18]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala	6 8 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1	5 77 3 37 5 50 954 954 9 9 9 9 9 9 9 9	297 14 0 6 3 39 136 07, df = 7 90) LC Events 1 2 0 0 0	 109 64 40 144 785 (P = 0. (P = 0. 31 30 38 229 10 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.8% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun	6 8 43 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1 0	5 77 3 37 5 50 954 954 9 9 9 9 9 9 9 9	297 14 0 6 3 39 136 07, df = 7 90) LC Events 1 2 0 0 0 1	 109 64 40 144 785 (P = 0. (P = 0. 31 50 38 229 10 111 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.8% 10.5% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% Cl</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect 2001 Edwards 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun 2019 Wu	6 8 43 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1 0 1 0 1	5 77 3 37 5 50 954 954 9 9 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 1 1 1 1 1 1 1	297 14 16 3 39 136 39 136 5 39 90 1 1 2 0 0 0 0 1 1	 109 64 40 144 785 7 (P = 0. 31 50 38 229 10 111 109 	 11.5% 12.3% 9.8% 18.3% 100.0% 1005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.8% 10.5% 13.6% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65%	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect Study or Subgroup 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun	6 8 43 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1 0	5 77 3 37 5 50 954 954 9 9 9 9 9 9 9 9	297 14 0 6 3 39 136 07, df = 7 90) LC Events 1 2 0 0 0 1	 109 64 40 144 785 (P = 0. (P = 0. 31 50 38 229 10 111 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.8% 10.5% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% Cl</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48]	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect 2001 Edwards 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun 2019 Wu	6 8 43 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1 0 1 0 1	5 77 3 37 5 50 954 954 9 9 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 1 1 1 1 1 1 1	297 14 16 3 39 136 39 136 5 39 90 1 1 2 0 0 0 0 1 1	 109 64 40 144 785 7 (P = 0. 31 50 38 229 10 111 109 64 	 11.5% 12.3% 9.8% 18.3% 100.0% 1005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.8% 10.5% 13.6% 	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65%	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun 2019 Wu 2020 Prassas	6 8 43 43 = 0.20; Ch t: Z = 0.13 Ll Events 0 0 1 9 1 0 1 0 1	5 77 3 37 5 50 954 954 954 954 954 954 955 196 954 956 956 956 956 956 956 956 956 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 9 9 9 9 9 9 9 9	297 14 16 3 39 136 39 136 5 39 90 1 1 2 0 0 0 0 1 1	 109 64 40 144 785 7 (P = 0. 31 50 38 229 10 111 109 64 	<pre>9 11.5% 9 12.3% 9 9.8% 9 9.8% 9 18.3% 9 100.0% 1005); ² = Weight 10.6% 11.6% 10.6% 12.9% 10.6% 10.5% 13.6% 19.5%</pre>	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65%	Favours [LI] Favours [LC] Risk Ratio
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect 2001 Edwards 2001 Edwards 2001 Edwards 2002 Law 2005 Gastinger 2008 Mala 2019 Sun 2019 Wu 2020 Prassas Total (95% CI)	6 8 43 43 = 0.20; Ch t: Z = 0.13 LI <u>Events</u> 0 0 1 9 1 0 1 3 3	5 77 3 37 5 50 954 954 954 954 954 954 955 196 954 956 956 956 956 956 956 956 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 9 9 9 9 9 9 9 9	297 14 0 6 3 39 138 07, df = 7 90) LC Events 1 2 0 0 0 0 0 1 1 1 1	 109 64 40 144 785 7 (P = 0. 31 50 38 229 10 111 109 64 642 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 10.6% <l< td=""><td>0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48] 1.42 [0.09, 22.29] 5.19 [0.56, 48.10] 1.35 [0.46, 4.01]</td><td>Favours [LI] Favours [LC]</td></l<>	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48] 1.42 [0.09, 22.29] 5.19 [0.56, 48.10] 1.35 [0.46, 4.01]	Favours [LI] Favours [LC]
D	2019 Wu 2020 Prassas 2022 Çaparlar 2023 Yang Total (95% CI) Total events Heterogeneity: Tau ² Test for overall effect 2001 Edwards 2001 Edwards 2001 Rullier 2002 Law 2005 Gastinger 2008 Mala 2019 Sun 2019 Sun 2019 Wu 2020 Prassas Total (95% CI) Total events	6 8 43 43 43 43 43 43 173 5 0.28; Chi ²	5 77 3 37 5 50 954 954 954 954 954 954 955 196 954 956 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 957 9 9 9 9 9 9 9 9	7 29 7 14 9 6 3 39 07, df = 7 90) LC Events 1 2 0 0 0 0 0 1 1 1 1 4 f = 7 (P	 109 64 40 144 785 7 (P = 0. 31 50 38 229 10 111 109 64 642 	 11.5% 12.3% 9.8% 18.3% 100.0% 005); ² = Weight 10.6% 10.6% <l< td=""><td>0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48] 1.42 [0.09, 22.29] 5.19 [0.56, 48.10] 1.35 [0.46, 4.01]</td><td>Favours [LI] Favours [LC] Risk Ratio</td></l<>	0.29 [0.13, 0.67] 0.99 [0.46, 2.13] 1.07 [0.40, 2.82] 0.81 [0.56, 1.18] 1.03 [0.68, 1.55] 65% Risk Ratio <u>M-H. Random, 95% CI</u> 0.32 [0.01, 7.65] 0.11 [0.01, 2.15] 3.25 [0.14, 77.25] 10.71 [0.63, 183.18] 0.61 [0.03, 14.04] 0.56 [0.02, 13.48] 1.42 [0.09, 22.29] 5.19 [0.56, 48.10] 1.35 [0.46, 4.01]	Favours [LI] Favours [LC] Risk Ratio

Fig. 7 The morbidity (A), mortality (B), stoma closure related complication (C) and anastomotic fistula (D) after stoma closure between LI and LC groups

		LI		LC			Risk Ratio	Risk Ratio
A	Study or Subgroup		Total		Total	Weight	M-H, Random, 95% C	
-	2001 Edwards	1	32	2	31	6.4%	0.48 [0.05, 5.07]	
	2001 Rullier	3	96	10	50	15.3%	0.16 [0.05, 0.54]	
	2002 Law	1	35	2	38	6.3%	0.54 [0.05, 5.73]	
	2008 Mala	2	53	0	10	4.3%	1.02 [0.05, 19.78]	
	2019 Sun	0	66	0	111		Not estimable	
	2019 Wu	3	77	22	109	16.3%	0.19 [0.06, 0.62]	
	2020 Prassas	5	37	5	64	16.3%	1.73 [0.54, 5.58]	
	2022 Çaparlar	3	50	2	40	10.0%	1.20 [0.21, 6.84]	
	2023 Yang	14	196	17	144	25.0%	0.61 [0.31, 1.19]	
	Total (95% CI)		642		597	100.0%	0.52 [0.27, 1.00]	•
	Total events	32		60				
	Heterogeneity: Tau ² =	0.33; Chi ²	= 11.8	6, df = 7 (P = 0.1	1); l ² = 41	%	
	Test for overall effect:					,,		0.01 0.1 1 10 100
								Favours [LI] Favours [LC]
В		LI		LC			Risk Ratio	Risk Ratio
D_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
	2001 Edwards	0	32	5	31	3.3%	0.09 [0.01, 1.53]	← • • • • • • • • • • • • • • • • • • •
	2001 Rullier	4	96	8	50	20.3%	0.26 [0.08, 0.82]	
	2019 Sun	4	66	8	111	19.9%	0.84 [0.26, 2.68]	
	2019 Wu	2	77	4	109	9.6%	0.71 [0.13, 3.77]	
	2020 Prassas	1	37	8	64	6.5%	0.22 [0.03, 1.66]	
	2022 Çaparlar	4	50	3	40	13.0%	1.07 [0.25, 4.49]	
	2023 Yang	7	196	8	144	27.4%	0.64 [0.24, 1.73]	
	Total (95% CI)		554		549	100.0%	0.53 [0.32, 0.89]	•
	Total events	22		44				
	Heterogeneity: Tau ² =	0.00; Chi²	= 5.61	, df = 6 (F	P = 0.47	'); l² = 0%		0.01 0.1 1 10 100
	Test for overall effect:	Z = 2.39 (P = 0.02	2)				Favours [LI] Favours [LC]
C		LI		LC			Risk Ratio	Risk Ratio
U_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl
	2002 Law	3	35	1	38	5.6%	3.26 [0.36, 29.87]	
	2005 Gastinger	17	407	2	229	12.8%	4.78 [1.11, 20.52]	
	2008 Mala	2	53	0	10	3.1%	1.02 [0.05, 19.78]	
	2019 Sun	4	66	3	111	12.7%	2.24 [0.52, 9.71]	
	2020 Prassas	0	37	0	64		Not estimable	
	2023 Yang	22	196	14	144	65.8%	1.15 [0.61, 2.18]	
	Total (95% CI)		794		596	100.0%	1.59 [0.94, 2.69]	◆
	Total events	48		20				
	Heterogeneity: Tau ² =	,		, i	P = 0.40); l² = 1%		0.01 0.1 1 10 100
	Test for overall effect:	Z = 1.74 (P = 0.0	8)				Favours [LI] Favours [LC]

Fig. 8 The Surgical site infections (A), Incisional hernia (B) and Ileus (C) after stoma closure between LI and LC groups

Operation time

Three studies [16, 18, 23] provided information on stoma closure operation time. The analysis showed no discernible difference between the LI and LC groups (MD: 3.45; 95%CI: -4.98–11.88; P=0.42; heterogeneity: P=0.05, I²=67%) (Fig. 9A).

Time to first defecation

The time to first defecation following stoma reversal was the subject of two studies [21, 23]. Thorough analysis revealed

no significant differences between the LI and LC groups (MD: -0.20; 95%CI: -0.49–0.09; P=0.19; heterogeneity: P=0.34, $I^2=0\%$) (Fig. 9B).

Discharge

Combining data from four studies [15, 18, 21, 23] indicated no statistically significant difference between the LI and LC groups' hospital stays following stoma reversal (MD: 0.06; 95%CI: -0.47–0.59; P=0.82; heterogeneity: P=0.13, I^2 =46%) (Fig. 9C).




Fig. 9 The Operation time (A), Time to first defecation (B) and Discharge (C) after stoma closure between LI and LC groups

Sensitivity analysis


The trial by Yang et al. [18] (RR: 0.59; 95%CI: 0.17–2.08; P = 0.42; $I^2 = 0\%$) significantly affected the effect size of the stoma retraction. The study by Ruiller et al. [19] (RR: 1.88; 95%CI: 1.14–3.11; P = 0.01; $I^2 = 60\%$) and the study of Law et al. [20] (RR: 1.90; 95%CI: 1.11-3.27; P=0.02; $I^2 = 62\%$) significantly affected the effect size of parastomal dermatitis after stoma formation. The study by Wu et al. [21] (RR: 2.43; 95%CI: 0.61–9.72; P=0.21; $I^2=0\%$) significantly affected the effect size of the dehydration or electrolyte imbalance after stoma formation. The trial by Yang et al. [18] (RR: 2.82; 95%CI: 0.45–17.58; P = 0.27; $I^2 = 0\%$), Edwards et al. [23] (RR: 7.32; 95%CI: 0.90-59.22; P = 0.06; I² = 30%) and Law et al. [20] (RR: 7.52; 95%CI: 0.96–59.22; P = 0.06; $I^2 = 28\%$) significantly affected the effect size of the high output. The study by Prassas et al. [16] (RR: 2.22; 95%CI: 0.85-5.80; $P = 0.10; I^2 = 0\%$) and Yang et al. [18] (RR: 2.20; 95%CI: 0.84–5.76; P = 0.11; $I^2 = 0\%$) significantly affected the effect size of the renal insufficiency after stoma formation. The study by Yang et al. [18] (RR: 1.44; 95%CI: 1.03–2.01; P = 0.03; $I^2 = 0\%$) significantly affected the effect size of the morbidity after stoma closure. Aditionally, the study by Yang et al. [18] (RR: 2.95; 95%CI: 1.21–7.20; P = 0.02; $I^2 = 0\%$) significantly affected the effect size of the ileus after stoma closure. The study by Rullier et al. [19] (RR: 0.64; 95%CI: 0.36–1.14; P = 0.13; $I^2 = 0\%$) affected the effect size of incisional hernia after stoma closure. Due to the small number of patients included, the subgroup analysis was limited.

Publication Bias

No significant publication bias regarding parastomal hernia after stoma formation or surgical site infections after stoma closure was observed in the funnel plots (Fig. 10).

Discussion

The preventive defunctioning stoma was performed to reduce reoperation morbidity and mortality in high-risk anastomose [26, 27]. Nevertheless, the optional type of protective ostomy remains a subject of debate. The choice of LI and LC for the stoma is somewhat arbitrary for surgeons. This meta-analysis was conducted to evaluate perioperative complications and complications of stoma closure with that of LI or LC formation during the early stages of anterior resection for rectal cancer.



First, the current study showed no discernible variations in morbidity and mortality among the early stages of anterior resection for rectal cancer, stoma creation, and stoma reversal. Both choices of ostomy are safe. Results of the present meta-analysis show that patients in the LI group had a lower incidence of stoma prolapse and retraction than those in the LC group. Prior investigations have also documented lower rates of stoma retraction rates in ileostomy compared to colostomy [28, 29]. Consistent with our findings, earlier meta-analyses have shown a 2% lower incidence of stoma prolapse in the LI group compared to an 11% prolapse rate in the LC group [30]. This

🖄 Springer

discrepancy could be attributed to the higher number of fascial defects resulting from transverse colostomy and the heavier content in the colon than in the ileum. Stoma retraction was frequently observed in female patients who underwent a protective colostomy because of the appearance of a skin fold at the waist over the upper abdomen due to a loose and floppy abdomen. Furthermore, our research revealed that the LI group experienced higher rates of renal insufficiency and high-output problems associated with their stoma than the LC group. One hypothesis is that the contents of ileum are more concentrated and diluted than those of the colon. According to reports. Up to 31% of small bowel stomas involve ileostomy, which frequently results in excessive output [31-33]. Complications such as dehydration, involving salt and water depletion, and renal impairment, can arise if the ileostomy output remains excessive [34–36]. Acute kidney injury (AKI) has been reported in 25% of patients receiving chemotherapy for ileostomy. AKI negatively affects adjuvant therapy, disease-free survival (DFS), and OS. Therefore, close attention should be paid to fluid balance and electrolyte management in patients with some degree of impaired renal function. The choice of ileostomy requires close monitoring and postoperative stoma care. A higher prevalence of peristomal skin irritation dermatitis is caused by the alkaline effluent produced by ileostomies, which is rich in proteolytic enzymes and irritates the exposed peristomal skin. Moreover, certain observational studies have shown that patients who underwent ileostomy are more prone to diarrhea, electrolyte abnormalities, and irritating dermatitis than those who underwent colostomy [37, 38]. However, our study found no significant difference in the incidence parastomotic dermatitis between the LI and LC groups. One possible explanation is the variation in the definitions of skin irritation used in different studies.

In contrast to LC, LI has a higher rate of ileus but a lower incidence of SSI and incisional hernia, according to our research. Incisional hernia is more common in the colostomy than in ileostomy [39, 40]. The significant fascial defect caused by the transverse colostomy may have caused of the higher incidence of incisional hernia in the LC group following stoma closure. Compared to the LI group, the LC group had a significantly higher incidence of SSI. The cleaner intestinal environment of the ileum compared to the colon could be the reason for this difference. Ileostomy has been shown to reduce the incidence of systemic infections, such as sepsis, in addition to local wound infections [41]. During surgery, incision protection devices can successfully shield the incision and prevent wound infection [42]. In the present study, the definition of ileus is different. Two studies [15, 20] reported intestinal obstruction and ileus [18], while other studies [16, 22] reported ileus. Therefore, the result regarding ileus require further consideration.

Several factors have been associated with AL, such as advanced age, BMI, male sex, ASA, and tumor size [43, 44]. In terms of BMI, sex, and ASA [28], the present review did not reveal any statistical differences between LI and LC. Considering that a significant percentage of patients are overweight or obese and that the elderly population is more susceptible to rectal cancer [1, 45], they often have a high risk of AL, making their choice of stoma prudent. However, older adults have relatively weak abdominal walls, which can increase the risk of stoma prolapse, colostomy development, and incisional hernias following colostomy reversal. Furthermore, individuals who are obese typically have shorter mesentery lengths and thicker subcutaneous layers, making colostomy more challenging. Therefore, Rosen et al. [46] showed that the usage of an ileostomy is recommended for patients who are obese, in whom adequate mobilization of the transverse colon is not possible. Furthermore, because the colostomy was located in the upper abdomen and somewhat farther from the radiation area, it would be a logical choice to perform the procedure if the patients needed a colostomy to receive postoperative radiation.

In addition to the abovementioned elements, it is important to highlight that the distal intestine lacks fecal stream stimulation for several months following stoma creation, which might affect physiology, particularly in the case of ileostomy. This stimulation involves mechanical forces, microorganisms, and microbial metabolites [47]. However, further studies are required to explore the relevant pathophysiological changes. When selecting a stoma type, patient's lifestyle choices and quality of life should also be taken into account. For instance, the patient's belt setting may clash with the location of the distal ileostomy in the lower abdomen, and heavy body hair in some patients may affect the effectiveness of the sticker chassis. Additionally, the odor of colon stoma secretions can be bothersome for some individuals. Therefore, it is crucial to consider each patient's unique needs, including their quality of life, sex, age, physiological state, body mass index (BMI), presence of obesity, and the timing of their treatment, when deciding whether to opt for protective colostomy or ileostomy. By taking these factors into account, a more informed and tailored decision regarding the type of ostomy procedure that is most suitable choice for each patient can be made.

Our analyses have some limitations. First, the results should be interpreted cautiously due to the inclusion of only two RCTs and eight cohort studies, with insufficient patients across these investigations. Consequently, the meta-analysis was weak, as expected event, such as parastomal dermatitis and renal insufficiency were low. Additionally, certain parameters, such as the operation time for stoma creation, and the size of the incision during stoma closure, should be compared between the two groups, whereas the included trials did not make the comparison. Moreover, the choice of surgical technique for stoma placement is a significant factor that could affect the duration of stoma formation and the likelihood of associated complications. In contrast to conventional fixation to the peritoneum and anterior rectal sheath, some surgeons advise the one-stitch method for creating protective loop ileostomies, which has the advantage of saving operating time [48]. Fewer studies have reported new methods to create loop colostomies. Finally, the high heterogeneity observed in this study for stoma-related complications,

stoma stricture, parastomal dermatitis, stoma closurerelated complications, and stoma closure operation time may be related to differences in the included study designs (including RCTS and retrospective studies), variations in the definitions of associated complications, and discrepancies in the length of the stoma reduction interval.

Conclusion

Our study suggests that compared to LC, LI is associated with a higher incidence of dehydration or electrolyte disturbance, high-output, and renal insufficiency, while demonstrating a reduced incidence of stoma prolapse and retraction, SSI, and incisional hernia. These findings suggest the use of a prophylactic diverting loop ileostomy during anterior rectal resection for rectal cancer. Naturally, patients with renal failure require additional monitoring. In addition, other individual patient characteristics such as obesity, physiological status, requirement for radiotherapy, and patient quality of life should be considered. Finally, further excellent prospective multicenter studies with large randomized controlled sample sizes are needed to provide additional confirmation of these findings.

Author contributions Shilai Yang, Donglin Du and Gang Tang participated in the conception, design and management of the study. Shilai Yang and Yudi Zhang conducted literature screening, and Shilai Yang and Dongling Du participated in the writing of the manuscript. Tang Gang analyzed the data and the manuscript was revised by Shilai Yang. Zhengqiang Wei oversaw the project. After a thorough evaluation, each author agreed to publish the final version of the manuscript.

Funding There was no funding.

Data availability No datasets were generated or analysed during the current study.

Declarations

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
- Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394(10207):1467–1480. https://doi.org/ 10.1016/S0140-6736(19)32319-0
- Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M (2018) Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci 19(9):2577. https://doi.org/10.3390/ijms19092577
- Heald RJ (1979) A new approach to rectal cancer. Br J Hosp Med 22(3):277–281
- Kim NK, Lim DJ, Yun SH, Sohn SK, Min JS (2001) Ultralow anterior resection and coloanal anastomosis for distal rectal cancer: functional and oncological results. Int J Colorectal Dis 16(4):234–237. https://doi.org/10.1007/s003840100306
- Di Cristofaro L, Ruffolo C, Pinto E, Massa M, Antoniutti M, Cagol M, Massani M, Alfieri R, Costa A, Bassi N, Castoro C, Scarpa M (2014) Complications after surgery for colorectal cancer affect quality of life and surgeon-patient relationship. Colorectal Dis 16(12):O407–O419. https://doi.org/10.1111/codi.12752
- Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP, International TaTME Registry Collaborative (2019) Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: results from the International TaTME registry. Ann Surg 269(4):700–711. https://doi.org/10.1097/SLA. 00000000002653
- Borstlap WAA, Westerduin E, Aukema TS, Bemelman WA, Tanis PJ, Dutch Snapshot Research Group (2017) Anastomotic leakage and chronic presacral sinus formation after low anterior resection: results from a large cross-sectional study. Ann Surg 266(5):870– 877. https://doi.org/10.1097/SLA.00000000002429
- Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, Lee WY (2016) Risk factors of anastomotic leakage and long-term survival after colorectal surgery. Med (Baltim) 95(8):e2890. https://doi. org/10.1097/MD.00000000002890
- Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, Chapuis PH, Bokey EL (2003) Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg 90(10):1261–1266. https://doi.org/10.1002/bjs.4219
- Krarup PM, Nordholm-Carstensen A, Jorgensen LN, Harling H (2014) Anastomotic leak increases distant recurrence and longterm mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg 259(5):930–938. https://doi.org/10. 1097/SLA.0b013e3182a6f2fc
- Moran B, Heald R (2000) Anastomotic leakage after colorectal anastomosis. Semin Surg Oncol 18(3):244–248. https://doi.org/10.1002/ (sici)1098-2388(200004/05)18:3<244::aid-ssu8>3.0.co;2-6
- Gessler B, Haglind E, Angenete E (2012) Loop ileostomies in colorectal cancer patients-morbidity and risk factors for nonreversal. J Surg Res 178(2):708–714. https://doi.org/10.1016/j.jss. 2012.08.018
- Kumar A, Daga R, Vijayaragavan P, Prakash A, Singh RK, Behari A, Kapoor VK, Saxena R (2011) Anterior resection for rectal carcinomarisk factors for anastomotic leaks and strictures. World J Gastroenterol 17(11):1475–1479. https://doi.org/10.3748/wjg.v17.i11.1475
- 15. Sun X, Han H, Qiu H, Wu B, Lin G, Niu B, Zhou J, Lu J, Xu L, Zhang G, Xiao Y (2019) Comparison of safety of loop ileostomy and loop transverse colostomy for low-lying rectal cancer patients

undergoing anterior resection: a retrospective, single institute, propensity score-matched study. J BUON 24(1):123–129

- Prassas D, Vossos V, Rehders A, Knoefel WT, Krieg A (2020) Loop ileostomy versus loop colostomy as temporary deviation after anterior resection for rectal cancer. Langenbecks Arch Surg 405(8):1147–1153. https://doi.org/10.1007/s00423-020-01940-w
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/ 10.1136/bmj.b2535
- Yang YW, Huang SC, Cheng HH, Chang SC, Jiang JK, Wang HS, Lin CC, Lin HH, Lan YT (2023) Protective loop ileostomy or colostomy? A risk evaluation of all common complications. Ann Coloproctol. https://doi.org/10.3393/ac.2022.00710.0101
- Rullier E, Le Toux N, Laurent C, Garrelon JL, Parneix M, Saric J (2001) Loop ileostomy versus loop colostomy for defunctioning low anastomoses during rectal cancer surgery. World J Surg 25(3):274-7; discussion 277-8. https://doi.org/10.1007/s0026 80020091
- Law WL, Chu KW, Choi HK (2002) Randomized clinical trial comparing loop ileostomy and loop transverse colostomy for faecal diversion following total mesorectal excision. Br J Surg 89(6):704–708. https://doi.org/10.1046/j.1365-2168.2002.02082.x
- Wu X, Lin G, Qiu H, Xiao Y, Wu B, Zhong M (2018) Loop ostomy following laparoscopic low anterior resection for rectal cancer after neoadjuvant chemoradiotherapy. Eur J Med Res 23(1):24. https://doi.org/10.1186/s40001-018-0325-x
- Gastinger I, Marusch F, Steinert R, Wolff S, Koeckerling F, Lippert H (2005) Working Group 'Colon/Rectum Carcinoma'. Protective defunctioning stoma in low anterior resection for rectal carcinoma. Br J Surg 92(9):1137–1142. https://doi.org/10.1002/bjs.5045
- Edwards DP, Leppington-Clarke A, Sexton R, Heald RJ, Moran BJ (2001) Stoma-related complications are more frequent after transverse colostomy than loop ileostomy: a prospective randomized clinical trial. Br J Surg 88(3):360–363. https://doi.org/10. 1046/j.1365-2168.2001.01727.x
- Mala T, Nesbakken A (2008) Morbidity related to the use of a protective stoma in anterior resection for rectal cancer. Colorectal Dis 10(8):785–788. https://doi.org/10.1111/j.1463-1318.2007.01456.x
- Caparlar MA, Dokcu S, Demirci S (2022) Loop ileostomy or loop transverse colostomy for resectable rectal cancers. Eur Res J 8:340–346. https://doi.org/10.18621/eurj.914951
- Matthiessen P, Hallböök O, Rutegård J, Simert G, Sjödahl R (2007) Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 246(2):207–214. https:// doi.org/10.1097/SLA.0b013e3180603024
- Boström P, Haapamäki MM, Rutegård J, Matthiessen P, Rutegård M (2018) Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer. BJS Open 3(1):106–111. https://doi.org/10.1002/bjs5.50106
- Sakai Y, Nelson H, Larson D, Maidl L, Young-Fadok T, Ilstrup D (2001) Temporary transverse colostomy vs loop ileostomy in diversion: a case-matched study. Arch Surg 136(3):338–342. https://doi.org/10.1001/archsurg.136.3.338
- Klink CD, Lioupis K, Binnebösel M, Kaemmer D, Kozubek I, Grommes J, Neumann UP, Jansen M, Willis S (2011) Diversion stoma after colorectal surgery: loop colostomy or ileostomy? Int J Colorectal Dis 26(4):431–436. https://doi.org/10.1007/ s00384-010-1123-2
- Gavriilidis P, Azoulay D, Taflampas P (2019) Loop transverse colostomy versus loop ileostomy for defunctioning of colorectal anastomosis: a systematic review, updated conventional metaanalysis, and cumulative meta-analysis. Surg Today 49(2):108– 117. https://doi.org/10.1007/s00595-018-1708-x

- Arenas Villafranca JJ, López-Rodríguez C, Abilés J, Rivera R, Gándara Adán N, Utrilla Navarro P (2015) Protocol for the detection and nutritional management of high-output stomas. Nutr J 14:45. https://doi.org/10.1186/s12937-015-0034-z
- 32. Takeda M, Takahashi H, Haraguchi N, Miyoshi N, Hata T, Yamamoto H, Matsuda C, Mizushima T, Doki Y, Mori M (2019) Factors predictive of high-output ileostomy: a retrospective single-center comparative study. Surg Today 49(6):482–487. https://doi.org/10.1007/s00595-018-1756-2
- Hara Y, Miura T, Sakamoto Y, Morohashi H, Nagase H, Hakamada K (2020) Organ/space infection is a common cause of high output stoma and outlet obstruction in diverting ileostomy. BMC Surg 20(1):83. https://doi.org/10.1186/s12893-020-00734-7
- Li L, Lau KS, Ramanathan V, Orcutt ST, Sansgiry S, Albo D, Berger DH, Anaya DA (2017) Ileostomy creation in colorectal cancer surgery: risk of acute kidney injury and chronic kidney disease. J Surg Res 210:204–212. https://doi.org/10.1016/j.jss. 2016.11.039
- Gessler B, Haglind E, Angenete E (2014) A temporary loop ileostomy affects renal function. Int J Colorectal Dis 29(9):1131–1135. https://doi.org/10.1007/s00384-014-1949-0
- Messaris E, Sehgal R, Deiling S, Koltun WA, Stewart D, McKenna K, Poritz LS (2012) Dehydration is the most common indication for readmission after diverting ileostomy creation. Dis Colon Rectum 55(2):175–180. https://doi.org/10.1097/DCR.0b013e31823d0ec5
- Manzenreiter L, Spaun G, Weitzendorfer M, Luketina R, Antoniou SA, Wundsam H, Koch OO, Emmanuel K (2018) A proposal for a tailored approach to diverting ostomy for colorectal anastomosis. Minerva Chir 73(1):29–35. https://doi.org/10.23736/S0026-4733.17.07486-7
- Caricato M, Ausania F, Ripetti V, Bartolozzi F, Campoli G, Coppola R (2007) Retrospective analysis of long-term defunctioning stoma complications after colorectal surgery. Colorectal Dis 9(6):559–561. https://doi.org/10.1111/j.1463-1318.2006.01187.x
- Tilney HS, Sains PS, Lovegrove RE, Reese GE, Heriot AG, Tekkis PP (2007) Comparison of outcomes following ileostomy versus colostomy for defunctioning colorectal anastomoses. World J Surg 31(5):1142–1151. https://doi.org/10.1007/s00268-006-0218-y
- Güenaga KF, Lustosa SA, Saad SS, Saconato H, Matos D (2007) Ileostomy or colostomy for temporary decompression of colorectal anastomosis. Cochrane Database Syst Rev 2007(1):CD004647. https://doi.org/10.1002/14651858.CD004647.pub2
- Klink CD, Willis S, Neumann UP, Jansen M (2010) Protective ileostoma versus protective transverse stoma. What evidence is available? Chirurg 81(11):974–977 German. https://doi.org/10. 1007/s00104-010-1930-6
- 42. Chinese Society of Surgical Infection and Intensive Care, Chinese Society of Surgery, Chinese Medical Association; Chinese College of Gastrointestinal Fistula Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association (2019) Chinese guideline for the prevention of surgical site infection. Zhonghua Wei Chang Wai Ke Za Zhi 22(4):301–314 Chinese. https://doi.org/10.3760/cma.j.issn.1671-0274.2019.04.001
- Sciuto A, Merola G, De Palma GD, Sodo M, Pirozzi F, Bracale UM, Bracale U (2018) Predictive factors for anastomotic leakage after laparoscopic colorectal surgery. World J Gastroenterol 24(21):2247–2260. https://doi.org/10.3748/wjg.v24.i21.2247
- Qu H, Liu Y, Bi DS (2015) Clinical risk factors for anastomotic leakage after laparoscopic anterior resection for rectal cancer: a systematic review and meta-analysis. Surg Endosc 29(12):3608– 3617. https://doi.org/10.1007/s00464-015-4117-x
- Bardou M, Rouland A, Martel M, Loffroy R, Barkun AN, Chapelle N (2022) Review article: obesity and colorectal cancer. Aliment Pharmacol Ther 56(3):407–418. https://doi.org/10.1111/apt.17045
- Rosen HR, Schiessel R (1999) Das Deviationsstoma [Loop enterostomy]. Chirurg 70(6):650-5. German. https://doi.org/10.1007/ s001040050701

- 47. Ma H, Li X, Pan Y, Wang L, Han B, Xie H, Zheng H, Jiang E, Chen J, Li Y, Ji G, Qiu Y, Xiao W (2023) Dissecting the effect of ileal faecal diversion on the intestine using single-cell sequencing. Clin Transl Med 13(7):e1321. https://doi.org/10.1002/ctm2.1321
- Chen Y, Pei W, Wang Q, Wang W, Xu T, Jing C, Li L, Zhang J (2020) One-stitch versus traditional method of protective loop ileostomy in laparoscopic low anterior rectal resection: a

retrospective comparative study. Int J Surg 80:117–123. https:// doi.org/10.1016/j.ijsu.2020.06.035

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.